Opening the door for hepatitis C virus infection in genetically humanized mice

Hepatology

Volumn 54, Issue 5, 2011, Pages 1873-1875

  Zeisel, Mirjam B ^a,b   Da Costa, Daniel ^a,b   Baumert, Thomas F ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CD81 ANTIGEN; CLAUDIN 1; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 2 RECEPTOR; OCCLUDIN; RAG2 PROTEIN; RECOMBINANT VACCINE; SCAVENGER RECEPTOR BI; VACCINIA VACCINE; VIRUS VECTOR;

ARTICLE; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPETENCE; IN VIVO CULTURE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS ENTRY; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS PATHOGENESIS;

EID: 80055042442     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24603     Document Type: Article

References (12)

1. Murray CL, Rice CM. Turning hepatitis C virus into a real virus. Annu Rev Microbiol 2011; doi:10.1146/annurev-micro-090110- 102954.
2. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 2006; 103: 7408-7413.
3. Scheel TK, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-alpha. Gastroenterology 2011; 140: 1032-1042.
4. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927-933.
5. Bissig KD, Wieland SF, Tran P, Isogawa M, Le TT, Chisari FV, et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 2010; 120: 924-930.
6. Barth H, Robinet E, Liang TJ, Baumert TF. Mouse models for the study of HCV infection and virus-host interactions. J Hepatol 2008; 49: 134-142.
7. Washburn ML, Bility MT, Zhang L, Kovalev GI, Buntzman A, Frelinger JA, et al. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 2011; 140: 1334-1344.
8. Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, et al. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011; 474: 208-211.
9. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009; 457: 882-886.
10. Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF. Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for antiviral therapies. J Hepatol 2011; 54: 566-576.
11. Fafi-Kremer S, Fofana I, Soulier E, Carolla P, Meuleman P, Leroux-Roels G, et al. Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med 2010; 207: 2019-2031.
12. Long G, Hiet MS, Windisch MP, Lee JY, Lohmann V, Bartenschlager R. Mouse hepatic cells support assembly of infectious hepatitis C virus particles. Gastroenterology 2011; doi:10.1053/j.gastro.2011.06.010.